Inventor · disambiguated record
Brenda L. Stevens
Also filed as: STEVENS BRENDA · STEVENS BRENDA L
18 granted patents·11 pending applications·69 citations·filing 2007–2024
93Inventor score
Files withBRISTOL MYERS SQUIBB CO20SILVERBACK THERAPEUTICS INC5UNIV ROCKEFELLER2ARARIS BIOTECH AG1RIXON MARK W1
Top patents by PatentIndex Score
29 records- 0197US10251945B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 9, 2019·20 cites·28 claims
- 0294US11179473B2Nectin-4 antibody conjugates and uses thereofSILVERBACK THERAPEUTICS INC·Filed 2021·Granted Nov 23, 2021·7 cites·30 claims
- 0394US10898556B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 26, 2021·7 cites·22 claims
- 0493US11207391B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 28, 2021·4 cites·20 claims
- 0593US8945553B2Bispecific antibodies to IL-23 and IL-17A/FBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Feb 3, 2015·16 cites·12 claims
- 0691US10493140B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 3, 2019·3 cites·21 claims
- 0787US10479838B2Antibodies to CD40 with enhanced agonist activityUNIV ROCKEFELLER·Filed 2016·Granted Nov 19, 2019·7 cites·10 claims
- 0884US2024336695A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0983US9708401B2IL-17A/F cross-reactive monoclonal antibodies and methods of using the sameBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jul 18, 2017·3 cites·12 claims
- 1081US2024041995A1Anti-icos agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1180US2022185877A1Antibody heavy chain constant domainsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1278US11306149B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 19, 2022·1 cites·20 claims
- 1375US9783606B2Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Oct 10, 2017·1 cites·71 claims
- 1474US11952427B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Apr 9, 2024·0 cites·20 claims
- 1574US11529399B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 20, 2022·0 cites·32 claims
- 1672US11254740B2Methods of treatment using IL-23p19 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 22, 2022·0 cites·24 claims
- 1768US2021054091A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1867US10844130B2Nucleic acids encoding an anti-CD40 antibodyBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 24, 2020·0 cites·16 claims
- 1967US10358489B2IL-23p19 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jul 23, 2019·0 cites·10 claims
- 2066US10358490B2Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodiesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jul 23, 2019·0 cites·18 claims
- 2165US12364768B2Nectin-4 antibody conjugates and uses thereofARARIS BIOTECH AG·Filed 2021·Granted Jul 22, 2025·0 cites·21 claims
- 2265US11541126B1Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereofSILVERBACK THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·0 cites·30 claims
- 2363US2023062712A1Anti-asgr1 antibody conjugates and uses thereofSILVERBACK THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2462US2017022272A1Il-23 antibodies and methods of using the sameBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 2559US2018142030A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 2652US2020071412A1Antibodies to cd40 with enhanced agonist activityUNIV ROCKEFELLER·Filed 2019·Application pending·0 cites
- 2750US2021130473A1TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOFSILVERBACK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2849US2022249685A1Anti-mesothelin antibodies and immunoconjugates thereofSILVERBACK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2941US2007197441A1Truncated il-17ra soluble receptor and methods of using in inflammationRIXON MARK W·Filed 2007·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →